Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase

Journal of Medicinal Chemistry

Volumn 45, Issue 5, 2002, Pages 1002-1018

  Mahboobi, Siavosh ^a   Teller, Steffen ^b   Pongratz, Herwig ^a   Hufsky, Harald ^a   Sellmer, Andreas ^a   Botzki, Alexander ^a   Uecker, Andrea ^b   Beckers, Thomas ^c   Baasner, Silke ^c   Schächtele, Christoph ^d   Überall, Florian ^e   Kassack, Matthias U ^f   Dove, Stefan ^a   Böhmer, Frank D ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c ASTA MEDICA AG   (Germany)

^d TUMOR BIOLOGY CENTER   (Germany)

^e UNIVERSITY OF INNSBRUCK   (Austria)

^f UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(5 HYDROXY 1H 2 INDOLYL)(1H 2 INDOLYL)METHANONE; [2 (1H 2 INDOLYLCARBONYL) 1H 5 INDOLYL]DIMETHYLAMINOETHANOATE; [2 (1H 2 INDOLYLCARBONYL) 1H 5 INDOLYL]METHOXYETHANOATE; ADENOSINE TRIPHOSPHATE; BIS(1H 2 INDOLYL)METHANONE; DIMETHYL SULFOXIDE; DNA; ENZYME INHIBITOR; INDOLE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL STRAIN 3T3; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FIBROSIS; MOUSE; NONHUMAN;

ANIMALS; CELL DIVISION; DNA; ENZYME INHIBITORS; GLYCINE; HUMANS; INDOLES; KETONES; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037186464     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010988n     Document Type: Article

References (56)

1. Structural and functional studies on platelet-derived growth factor
2. Mechanism of action of platelet-derived growth factor
3. Platelet-derived growth factor receptor signals
4. Platelet-derived growth-factor - A key regulator of connective-tissue cells in embryogenesis and pathogenesis
5. PDGF-Receptor tyrosine kinase blocker AG1295 selectively attenuates smooth-muscle cell-growth in-vitro and reduces neointimal formation after balloon angioplasty in swine
6. Substantial inhibition of neointimal response to balloon injury in the rat carotid-artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth-factor
7. Stimulated activation of platelet-derived growth-factor receptor in-vivo in balloon-injured arteries - A link between angiotensin-II and intimal thickening
8. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop
9. Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor
10. Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line
11. Fusion of PDGF receptor beta to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with T(512) chromosomal translocation
12. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR-beta oncoprotein
13. Expression in lung carcinomas of platelet-derived growth-factor and its receptors
14. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling
15. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase
16. A new series of PDGF receptor tyrosine kinase inhibitors: 3-Substituted quinoline derivatives
17. Tyrphostins. 5. Potent inhibitors of platelet-derived growthfactor receptor tyrosine kinase-structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins
18. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation
19. Phosphorylation site-specific inhibition of platelet-derived growth-factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296
20. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
21. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors
22. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class
23. Structure-activity relationships for 1-phenylben-zimidazoles as selective ATP site inhibitors of the plateletderived growth factor receptor
24. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases
25. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
26. Identification of substituted 3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-rbeta tyrosine kinases
27. Inhibition of platelet-derived growth factor-mediated signal-transduction and tumor-growth by N-[4-(Trifluorom-ethyl)-phenyl] 5-methylisoxazole-4-carboxamide
28. Pyrrolo(3, 4)-betacarboline-diones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase
29. Homo-Arcyriaflavin: The Synthesis of Ring-expanded arcyriaflavin analogues
30. Syntheses by means of magnesylpyrrole. Series I.I. Note X
31. The Reaction of indole and the indole grignard reagent with phosgene. A facile Synthesis of indole-3-carboxylic acid derivatives
32. Electrophilic substitution in indoles. Part 15. The reaction between methylenedi-indoles and p-nitrobenzenediazonium fluoroborate
33. Bergmann synthesis of 6-formylindolo[3,2-b]-carbazole, an extremely potent ligand for the aryl hydrogen (Ah) receptor
34. The Leimgruber-Batcho indole synthesis
35. The synthesis of 2-thianaphthal-dehyde and some of its derivatives
36. Sur quelques propriétés du formyl-2 benzofuran
37. Crystal-structure-based design and synthesis of novel c-terminal inhibitors of HIV protease
38. Novel indole-2-carboxamide and cycloalkeno[1,2-b]indole derivatives. Structure-activity relationships for high inhibition of human LDL peroxidation
39. Transformations with chlorotrimethylsilane/sodium iodide, a convenient in situ iodotrimethylsilane reagent
40. A receptors
41. th Sir Hans Krebs lecture: Knowledge-based protein modelling and design
42. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism
43. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
44. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
45. Binding models for inhibitors of the receptor tyrosine kinases PDGFR-β and FGFR-1
46. 2-Substituted aminopyrido [2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity
47. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
48. Ab1 protein-tyrosine kinase inhibitor STI-571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
49. Total synthesis of galantin I. Acid-catalyzed cyclization of galatinic acid
50. A general procedure for mild and rapid reduction of aliphatic and aromatic nitro compounds using ammonium formate as a catalytic hydrogen transfer agent
51. Syntheses with N-protected 2-lithioindoles
52. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling
53. Molecular modeling of G-protein coupled receptor kinase 2: Docking and biochemical evaluation of inhibitors
54. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
55. Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase